Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines
Authors:
- Nanette L. BondNBNanette L. Bond
- John M. ZahradnikJZJohn M. Zahradnik
- Tod A. CramtonTCTod A. Cramton
- John B. RobbinsJRJohn B. Robbins
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Oral immunisation against typhoid fever in Indonesia with Ty21a vaccineThe Lancet, 1991
- Salmonella typhi Infections in the United States, 1975-1984: Increasing Role of Foreign TravelClinical Infectious Diseases, 1989
- Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid feverVaccine, 1988
- PROTECTIVE ACTIVITY OF VI CAPSULAR POLYSACCHARIDE VACCINE AGAINST TYPHOID FEVERThe Lancet, 1987
- Prevention of Typhoid Fever in Nepal with the VI Capsular Polysaccharide ofSalmonella TyphiNew England Journal of Medicine, 1987
- LARGE-SCALE FIELD TRIAL OF TY21A LIVE ORAL TYPHOID VACCINE IN ENTERIC-COATED CAPSULE FORMULATIONThe Lancet, 1987
- Inefficacy of the commercial live oral Ty 21a vaccine in the prevention of typhoid feverEuropean Journal of Clinical Microbiology & Infectious Diseases, 1985
- HUMAN IMMUNITY TO THE MENINGOCOCCUSJournal of Experimental Medicine, 1969
- A SEVEN-YEAR FIELD TRIAL OF TWO TYPHOID VACCINES IN GUYANAThe Lancet, 1967
- THE INFLUENCE OF DOSAGE AND ROUTE OF INJECTION ON THE ANTIBODY RESPONSE OF HUMAN SUBJECTS TO THE SPECIFIC CARBOHYDRATE OF THE TYPE VIII PNEUMOCOCCUS 1Journal of Clinical Investigation, 1935